EUVIMEDEUVIMED entdecken
Crossref

Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors

Yihui Song, Xiangli Ren, Xinyu Yang, Jinbo Xiong, Wenwen Wang, Kai Tang, Bin Yu iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yihui Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Antineoplastic Agents, Pyrimidinones, Pyrazoles. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, Fujian Medical University, Key Scientific Research Project of Colleges and Universities in Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) plays crucial roles in various biological processes and has become a promising target for cancer therapy. In this work, we presented the structure-guided design of new allosteric SHP2 inhibitors, leading to the identification of the pyrazolopyrimidinone derivatives TK-684 and TK-685. Both compounds were highly potent and selective allosteric SHP2 inhibitors (TK-684: SHP2WT IC50 = 2.1 nM; Ki = 0.89 nM; TK-685: SHP2WT IC50 = 1.5 nM; Ki = 0.87 nM), likely binding to the "tunnel" allosteric site of SHP2. By targeting SHP2-mediated AKT and ERK signaling pathways, TK-684 and TK-685 suppressed cell proliferation and induced apoptosis in esophageal cancer cells. Additionally, oral administration of TK-685 demonstrated good antitumor effects in the KYSE-150 xenograft mouse model, with a T/C value of 76.8%. Collectively, the pyrazolopyrimidinone derivatives represent promising lead compounds for the treatment of esophageal cancer, where SHP2 is dysregulated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 11Antineoplastic AgentsPyrimidinonesPyrazolesDrug DesignEnzyme InhibitorsHumansAnimalsStructure-Activity RelationshipCell ProliferationMiceAllosteric RegulationCell Line, TumorApoptosisMice, NudeXenograft Model Antitumor AssaysEsophageal NeoplasmsMolecular Docking Simulation

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 11Antineoplastic AgentsPyrimidinonesPyrazolesEnzyme InhibitorsPTPN11 protein, human

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fujian Medical University, Fuzhou 350122, China.
  • Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.

ORCID-Profile: Bin Yu

Förderung

  • Natural Science Foundation of Henan Province
  • Fujian Medical University
  • Key Scientific Research Project of Colleges and Universities in Henan Province
  • National Natural Science Foundation of China
  • Chunhui Project Foundation of the Education Department of China

Zitieren

APA

Song, Y., Ren, X., Yang, X., Xiong, J., Wang, W., Tang, K., & Yu, B. (2025). Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00524

Vancouver

Song Y, Ren X, Yang X, Xiong J, Wang W, Tang K, et al. Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00524

BibTeX
@article{Song2025,
  author = {Song, Yihui and Ren, Xiangli and Yang, Xinyu and Xiong, Jinbo and Wang, Wenwen and Tang, Kai and Yu, Bin},
  title = {Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00524}
}
Kostenlos starten →